New updates have been reported about Circular Genomics.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Circular Genomics has entered a strategic alliance with Vitazi.ai to develop a multimodal diagnostic workflow that combines AI-powered retinal imaging with circular RNA blood biomarkers for earlier identification and risk stratification of Alzheimer’s disease. The partnership is designed to expand the commercial reach of Circular Genomics’ circRNA platform, address the underdiagnosis of early-stage patients, and create new channels into primary care and optometry settings.
Under the collaboration, Vitazi.ai’s retinal imaging analytics will be integrated with Circular Genomics’ proprietary circRNA biomarker data through shared machine learning models to deliver non-invasive screening followed by molecular confirmation. The envisioned two-step workflow uses AI-based retinal triage in frontline clinics to flag at-risk individuals, then applies blood-based circRNA testing to validate disease biology and provide pathway-level insight that goes beyond traditional protein markers.
Circular Genomics expects this architecture to support broader, earlier patient identification, enabling more efficient deployment of disease-modifying therapies and creating opportunities for pharmaceutical partnerships in trial enrichment, patient stratification, and real-world evidence programs. CEO Paul Sargeant, PhD, described the alliance as a catalyst for scaling early Alzheimer’s detection and accelerating the company’s market penetration across both primary and specialty care.
The initial phase of the collaboration will focus on building joint predictive models that fuse structural retinal data with molecular circRNA profiles to generate early diagnostic and progression-risk outputs for Alzheimer’s. Circular Genomics’ CSO and Co-Founder Nikolaos Mellios, MD, PhD, emphasized that combining orthogonal biological signals represents a step-change in modeling neurodegenerative disease biology, with potential applicability beyond Alzheimer’s across the firm’s broader precision neurology roadmap.
From a strategic standpoint, the alliance positions Circular Genomics to leverage the stability, brain enrichment, and blood–brain barrier penetration characteristics of circRNAs to differentiate its offering in a crowded neurodegenerative diagnostics landscape. By anchoring its platform in scalable, low-infrastructure retinal screening augmented by high-specificity molecular confirmation, the company is targeting a significant diagnostic gap that has both substantial clinical importance and attractive economic upside for healthcare systems, payers, and life sciences partners.
If successfully validated and adopted, this two-step workflow could enhance Circular Genomics’ role as a key enabler of value-based care in neurology by improving case finding, reducing delays in diagnosis, and better aligning patients with appropriate therapies earlier in the disease course. The collaboration reinforces the company’s positioning as a precision neurology leader and is likely to inform future product development, partnership structures, and commercialization strategies within the neurodegenerative disease market.